ReviewFrontiers in oncology2026
Targeting the PRMT1 axis in cancer: from epigenetic plasticity to contextual therapeutic interventions.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein arginine methyltransferase 1 (PRMT1), the predominant Type I arginine methyltransferase, is reported to play the key role in regulating cancer epigenetics. Its activity directs gene expression, chromatin structure and transcriptional activation by mediating asymmetric dimethylation of histone and non-histone proteins. Despite extensive characterization of PRMT1 as a dominant arginine methyltransferase, its paradoxical oncogenic and tumor-suppressive roles have remained conceptually fragmented. This review integrates isoform-specific biology, chromatin crosstalk, and emerging therapeutic strategies to resolve this paradox and provide a translational framework for PRMT1-targeted precision oncology. PRMT1 exhibits context-dependent activity. While it predominantly functions as an oncogenic regulator in both solid tumors and hematological malignancies, emerging evidence indicates that PRMT1 may also exert tumor-suppressive effects under specific metabolic, apoptotic, and microenvironmental contexts. This differential behavior is mediated by chromatin remodeling, transcription factor recruitment, enhancer-promoter interactions, and its interplay with key epigenetic regulators such as EZH2, leukemogenic fusion proteins like MLL-AF9, and non-coding RNAs. As a drug target, PRMT1 has gained significant attention, with several small-molecule inhibitors demonstrating efficacy in preclinical and early clinical studies. However, challenges such as off-target effects and resistance highlight the need for a deeper mechanistic understanding of its cancer-specific roles. By synthesizing current insights, this review elucidates PRMT1's multifaceted role in cancer biology and underscores its potential as a target for precision oncology, laying the groundwork for future therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.